Angiogenesis and its therapeutic implication. 5. Bone marrow angiogenesis and anti-angiogenic therapy in multiple myeloma

Research output: Contribution to journalArticle

Abstract

In summary, increased bone marrow MVD as well as plasma concentrations of angiogenic growth factors are correlated with disease activity in MM. These results suggest that bone marrow angiogenesis may be an important factor for disease progression and can also be a therapeutic target. Thalidomide, known as an inhibitor of angiogenesis, was effective for the treatment of refractory MM. However, special caution must be paid to it's adverse effects.

Original languageEnglish
Pages (from-to)303-305
Number of pages3
JournalInternal Medicine
Volume42
Issue number3
Publication statusPublished - 2003 Mar 1

Fingerprint

Multiple Myeloma
Bone Marrow
Thalidomide
Angiogenesis Inhibitors
Angiogenesis Inducing Agents
Disease Progression
Intercellular Signaling Peptides and Proteins
Therapeutics

Keywords

  • Angiogenic growth factors
  • Multiple myeloma
  • Thalidomide
  • Tumor angiogenesis

ASJC Scopus subject areas

  • Internal Medicine

Cite this

@article{48ae79635ae54fe1bea98731e674538b,
title = "Angiogenesis and its therapeutic implication. 5. Bone marrow angiogenesis and anti-angiogenic therapy in multiple myeloma",
abstract = "In summary, increased bone marrow MVD as well as plasma concentrations of angiogenic growth factors are correlated with disease activity in MM. These results suggest that bone marrow angiogenesis may be an important factor for disease progression and can also be a therapeutic target. Thalidomide, known as an inhibitor of angiogenesis, was effective for the treatment of refractory MM. However, special caution must be paid to it's adverse effects.",
keywords = "Angiogenic growth factors, Multiple myeloma, Thalidomide, Tumor angiogenesis",
author = "Yutaka Hattori",
year = "2003",
month = "3",
day = "1",
language = "English",
volume = "42",
pages = "303--305",
journal = "Internal Medicine",
issn = "0918-2918",
publisher = "Japanese Society of Internal Medicine",
number = "3",

}

TY - JOUR

T1 - Angiogenesis and its therapeutic implication. 5. Bone marrow angiogenesis and anti-angiogenic therapy in multiple myeloma

AU - Hattori, Yutaka

PY - 2003/3/1

Y1 - 2003/3/1

N2 - In summary, increased bone marrow MVD as well as plasma concentrations of angiogenic growth factors are correlated with disease activity in MM. These results suggest that bone marrow angiogenesis may be an important factor for disease progression and can also be a therapeutic target. Thalidomide, known as an inhibitor of angiogenesis, was effective for the treatment of refractory MM. However, special caution must be paid to it's adverse effects.

AB - In summary, increased bone marrow MVD as well as plasma concentrations of angiogenic growth factors are correlated with disease activity in MM. These results suggest that bone marrow angiogenesis may be an important factor for disease progression and can also be a therapeutic target. Thalidomide, known as an inhibitor of angiogenesis, was effective for the treatment of refractory MM. However, special caution must be paid to it's adverse effects.

KW - Angiogenic growth factors

KW - Multiple myeloma

KW - Thalidomide

KW - Tumor angiogenesis

UR - http://www.scopus.com/inward/record.url?scp=0037367703&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037367703&partnerID=8YFLogxK

M3 - Article

C2 - 12705806

AN - SCOPUS:0037367703

VL - 42

SP - 303

EP - 305

JO - Internal Medicine

JF - Internal Medicine

SN - 0918-2918

IS - 3

ER -